Download PDF
Digestive Disease Interventions 2020; 04(02): 134-147
DOI: 10.1055/s-0040-1712146
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions

Raazi Bajwa
1   Division of Interventional Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
,
David C. Madoff
2   Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut
,
Sirish A. Kishore
1   Division of Interventional Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
› Author Affiliations Disclosure This work was in part funded by Dr. Madoff's NIH grant R01CA206180.
Further Information

Publication History

12 February 2020

15 April 2020

Publication Date:
25 May 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Primary and secondary liver cancers are a major cause of mortality worldwide. Transarterial liver-directed therapy, or embolotherapy, represents an important locoregional treatment strategy for primary and secondary liver tumors. Embolotherapeutic modalities include bland embolization (transarterial embolization), chemoembolization (transarterial chemoembolization), and radioembolization or selective internal radiotherapy. A brief technical overview of embolotherapeutic modalities as well as supportive evidence for the treatment of most common primary and secondary liver tumors will be discussed in this review. Several potential future applications, including synergy with systemic therapy, interventional theranostics, and artificial intelligence will also be reviewed briefly.

Keywords

embolization - liver cancer - locoregional therapy

Disclaimer

Since Dr. David C. Madoff is the co-Editor in Chief of the journal, Dr. Baljendra Kapoor served as ad-hoc Editor for this manuscript.


 

  • References

  • 1 Akinyemiju T, Abera S, Ahmed M. , et al; Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017; 3 (12) 1683-1691
    CrossrefPubMedGoogle Scholar
  • 2 Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. 2004; 127 (5 Suppl): S5-S16
    PubMedGoogle Scholar
  • 3 Vargas GM, Parmar AD, Sheffield KM, Tamirisa NP, Brown KM, Riall TS. Impact of liver-directed therapy in colorectal cancer liver metastases. J Surg Res 2014; 191 (01) 42-50
    CrossrefPubMedGoogle Scholar
  • 4 Park J, Chen YJ, Lu WP, Fong Y. The evolution of liver-directed treatments for hepatic colorectal metastases. Oncology (Williston Park) 2014; 28 (11) 991-1003
    PubMedGoogle Scholar
  • 5 Nanashima A, Takeshita H, Abo T. , et al. Recent advances and significance of intra-arterial infusion chemotherapy in non-resectable colorectal liver metastasis. J Gastrointest Oncol 2013; 4 (02) 164-172
    PubMedGoogle Scholar
  • 6 Chapman WC, Klintmalm G, Hemming A. , et al. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified?. J Am Coll Surg 2015; 220 (04) 628-637
    CrossrefPubMedGoogle Scholar
  • 7 Chegai F, Orlacchio A, Merolla S, Monti S, Mannelli L. Intermediate hepatocellular carcinoma: the role of transarterial therapy. Hepat Oncol 2015; 2 (04) 399-408
    PubMedGoogle Scholar
  • 8 Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30 (05) 969-977
    PubMedGoogle Scholar
  • 9 Brown DB, Geschwind JFH, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2009; 20 (7, Suppl) S317-S323
    CrossrefPubMedGoogle Scholar
  • 10 Lewandowski RJ, Wang D, Gehl J. , et al. A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring. J Vasc Interv Radiol 2007; 18 (10) 1249-1257
    CrossrefPubMedGoogle Scholar
  • 11 Jin B, Wang D, Lewandowski RJ. , et al. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol 2011; 196 (04) 919-928
    CrossrefPubMedGoogle Scholar
  • 12 Hu J, Maybody M, Cao G. , et al. Lipiodol retention pattern assessed by cone beam computed tomography during conventional transarterial chemoembolization of hepatocellular carcinoma: accuracy and correlation with response. Cancer Imaging 2016; 16 (01) 32
    CrossrefPubMedGoogle Scholar
  • 13 Benson III AB, D'Angelica MI, Abbott DE. , et al. NCCN guidelines insights: hepatobiliary cancers, version 1.2017. J Natl Compr Canc Netw 2017; 15 (05) 563-573
    CrossrefPubMedGoogle Scholar
  • 14 Mahnken AH, Pereira PL, de Baère T. Interventional oncologic approaches to liver metastases. Radiology 2013; 266 (02) 407-430
    CrossrefPubMedGoogle Scholar
  • 15 Riaz A, Salem R. Liver tumors: metastases. In: Transcatheter Embolization and Therapy. Kessel D, Ray C. , eds. London: Springer; 2010: 197-203
    CrossrefGoogle Scholar
  • 16 Kim BK, Kim SU, Kim KA. , et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol 2015; 62 (06) 1304-1310
    CrossrefPubMedGoogle Scholar
  • 17 Rose SC, Narsinh KH, Isaacson AJ, Fischman AM, Golzarian J. The beauty and bane of pressure-directed embolotherapy: hemodynamic principles and preliminary clinical evidence. AJR Am J Roentgenol 2019; 212 (03) 686-695
    CrossrefPubMedGoogle Scholar
  • 18 Rose SC, Lim GM, Arellano RS, Easter DB, Roberts AC. Temporary splenic artery balloon occlusion for protection of nonsplenic vascular beds during splenic embolization. AJR Am J Roentgenol 1998; 170 (05) 1186-1188
    CrossrefPubMedGoogle Scholar
  • 19 Rose SC, Halstead GD, Narsinh KH. Pressure-directed embolization of hepatic arteries in a porcine model using a temporary occlusion balloon microcatheter: proof of concept. Cardiovasc Intervent Radiol 2017; 40 (11) 1769-1776
    CrossrefPubMedGoogle Scholar
  • 20 Maruyama M, Yoshizako T, Nakamura T, Nakamura M, Yoshida R, Kitagaki H. Initial experience with balloon-occluded trans-catheter arterial chemoembolization (B-TACE) for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2016; 39 (03) 359-366
    CrossrefPubMedGoogle Scholar
  • 21 Newgard BJ, Getrajdman GI, Erinjeri JP. , et al. Incidence and consequence of nontarget embolization following bland hepatic arterial embolization. Cardiovasc Intervent Radiol 2019; 42 (08) 1135-1141
    CrossrefPubMedGoogle Scholar
  • 22 Arepally A, Chomas J, Kraitchman D, Hong K. Quantification and reduction of reflux during embolotherapy using an antireflux catheter and tantalum microspheres: ex vivo analysis. J Vasc Interv Radiol 2013; 24 (04) 575-580
    CrossrefPubMedGoogle Scholar
  • 23 Titano JJ, Fischman AM, Cherian A. , et al. End-hole versus microvalve infusion catheters in patients undergoing drug-eluting microspheres-TACE for solitary hepatocellular carcinoma tumors: a retrospective analysis. Cardiovasc Intervent Radiol 2019; 42 (04) 560-568
    CrossrefPubMedGoogle Scholar
  • 24 Cheng JC-H, Wu J-K, Lee PC-T. , et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2004; 60 (05) 1502-1509
    CrossrefPubMedGoogle Scholar
  • 25 Dawson LA, Guha C. Hepatocellular carcinoma: radiation therapy. Cancer J 2008; 14 (02) 111-116
    CrossrefPubMedGoogle Scholar
  • 26 Gabr A, Polineni P, Mouli SK, Riaz A, Lewandowski RJ, Salem R. Neoadjuvant radiation lobectomy as an alternative to portal vein embolization in hepatocellular carcinoma. Semin Nucl Med 2019; 49 (03) 197-203
    CrossrefPubMedGoogle Scholar
  • 27 Vouche M, Lewandowski RJ, Atassi R. , et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 2013; 59 (05) 1029-1036
    CrossrefPubMedGoogle Scholar
  • 28 Malhotra A, Liu DM, Talenfeld AD. Radiation segmentectomy and radiation lobectomy: a practical review of techniques. Tech Vasc Interv Radiol 2019; 22 (02) 49-57
    CrossrefPubMedGoogle Scholar
  • 29 Riaz A, Gates VL, Atassi B. , et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011; 79 (01) 163-171
    CrossrefPubMedGoogle Scholar
  • 30 Salem R, Gabr A, Riaz A. , et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology 2018; 68 (04) 1429-1440
    CrossrefPubMedGoogle Scholar
  • 31 Sofocleous CT, Boas FE. Radiation segmentectomy for hepatocellular carcinoma: ready for prime time?. Radiology 2018; 287 (03) 1059-1060
    CrossrefPubMedGoogle Scholar
  • 32 Jakobs TF, Hoffmann RT, Dehm K. , et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 2008; 19 (08) 1187-1195
    CrossrefPubMedGoogle Scholar
  • 33 Piscaglia F, Ogasawara S. Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment. Liver Cancer 2018; 7 (01) 104-119
    CrossrefPubMedGoogle Scholar
  • 34 Raoul JL, Sangro B, Forner A. , et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37 (03) 212-220
    CrossrefPubMedGoogle Scholar
  • 35 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol 2015; 62 (05) 1187-1195
    CrossrefPubMedGoogle Scholar
  • 36 Lange N, Dufour JF. Changing epidemiology of HCC: how to screen and identify patients at risk?. Dig Dis Sci 2019; 64 (04) 903-909
    CrossrefPubMedGoogle Scholar
  • 37 Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150 (04) 835-853
    CrossrefPubMedGoogle Scholar
  • 38 Kim RD, Kim JS, Watanabe G, Mohuczy D, Behrns KE. Liver regeneration and the atrophy-hypertrophy complex. Semin Intervent Radiol 2008; 25 (02) 92-103
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Tustumi F, Ernani L, Coelho FF. , et al. Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford) 2018; 20 (12) 1109-1118
    CrossrefPubMedGoogle Scholar
  • 40 Glantzounis GK, Tokidis E, Basourakos S-P, Ntzani EE, Lianos GD, Pentheroudakis G. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol 2017; 43 (01) 32-41
    CrossrefPubMedGoogle Scholar
  • 41 Yoo H, Kim JH, Ko G-Y. , et al. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma. Ann Surg Oncol 2011; 18 (05) 1251-1257
    CrossrefPubMedGoogle Scholar
  • 42 Teo J-Y, Allen Jr JC, Ng DC. , et al. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. HPB (Oxford) 2016; 18 (01) 7-12
    CrossrefPubMedGoogle Scholar
  • 43 Coletta M, Nicolini D, Benedetti Cacciaguerra A, Mazzocato S, Rossi R, Vivarelli M. Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same?. Transl Gastroenterol Hepatol 2017; 2: 78
    CrossrefPubMedGoogle Scholar
  • 44 Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl 2013; 19 (12) 1343-1353
    CrossrefPubMedGoogle Scholar
  • 45 Tohme S, Sukato D, Chen H-W. , et al. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. J Vasc Interv Radiol 2013; 24 (11) 1632-1638
    CrossrefPubMedGoogle Scholar
  • 46 Pauwels X, Azahaf M, Lassailly G. , et al. Drug-eluting beads loaded with doxorubicin (DEBDOX) chemoembolisation before liver transplantation for hepatocellular carcinoma: an imaging/histologic correlation study. Cardiovasc Intervent Radiol 2015; 38 (03) 685-692
    CrossrefPubMedGoogle Scholar
  • 47 Hodavance MS, Vikingstad EM, Griffin AS. , et al. Effectiveness of transarterial embolization of hepatocellular carcinoma as a bridge to transplantation. J Vasc Interv Radiol 2016; 27 (01) 39-45
    CrossrefPubMedGoogle Scholar
  • 48 Salem R, Gordon AC, Mouli S. , et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016; 151 (06) 1155.e2-1163.e2
    CrossrefPubMedGoogle Scholar
  • 49 DiNorcia J, Florman SS, Haydel B. , et al. Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. Ann Surg 2020; 271 (04) 616-624
    CrossrefPubMedGoogle Scholar
  • 50 Agopian VG, Morshedi MM, McWilliams J. , et al. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients. Ann Surg 2015; 262 (03) 536-545 , discussion 543–545
    CrossrefPubMedGoogle Scholar
  • 51 Vouche M, Habib A, Ward TJ. , et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014; 60 (01) 192-201
    CrossrefPubMedGoogle Scholar
  • 52 Clavien P-A, Lesurtel M, Bossuyt PMM, Gores GJ, Langer B, Perrier A. ; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13 (01) e11-e22
    CrossrefPubMedGoogle Scholar
  • 53 Heimbach JK, Kulik LM, Finn RS. , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67 (01) 358-380
    CrossrefPubMedGoogle Scholar
  • 54 Galle PR, Forner A, Llovet JM. , et al; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
    CrossrefPubMedGoogle Scholar
  • 55 Yang H-J, Lee J-H, Lee DH. , et al. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology 2014; 271 (03) 909-918
    CrossrefPubMedGoogle Scholar
  • 56 Biederman D, Titano J, Bishay V. , et al. Radiation segmentectomy vs. microwave ablation for unresectable solitary hepatocellular carcinoma ≤3 cm: a propensity score matching study. J Vasc Interv Radiol 2016; 27 (03) S5-S6
    CrossrefPubMedGoogle Scholar
  • 57 Miyayama S. Ultraselective conventional transarterial chemoembolization: When and how?. Clin Mol Hepatol 2019; 25 (04) 344-353
    CrossrefPubMedGoogle Scholar
  • 58 Kuroda C, Sakurai M, Monden M. , et al. Limitation of transcatheter arterial chemoembolization using iodized oil for small hepatocellular carcinoma. A study in resected cases. Cancer 1991; 67 (01) 81-86
    CrossrefPubMedGoogle Scholar
  • 59 Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol 1989; 23 (Suppl): S4-S8
    CrossrefPubMedGoogle Scholar
  • 60 Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49 (05) 523-529
    CrossrefPubMedGoogle Scholar
  • 61 Zen C, Zen Y, Mitry RR. , et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl 2011; 17 (08) 943-954
    CrossrefPubMedGoogle Scholar
  • 62 O'Hara R. A novel method for imaging pressure and flow in solid tumors of the liver. Cardiovasc Intervent Radiol 2018; 41 (Suppl. 02) 17-49
    CrossrefPubMedGoogle Scholar
  • 63 Lewandowski RJ, Gabr A, Abouchaleh N. , et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 2018; 287 (03) 1050-1058
    CrossrefPubMedGoogle Scholar
  • 64 Labgaa I, Tabrizian P, Titano J. , et al. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. HPB (Oxford) 2019; 21 (11) 1497-1504
    CrossrefPubMedGoogle Scholar
  • 65 Llovet JM, Ducreux M, Lencioni R. , et al; European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (04) 908-943
    CrossrefPubMedGoogle Scholar
  • 66 Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl 2015; 21 (09) 1142-1152
    CrossrefPubMedGoogle Scholar
  • 67 Bryce K, Tsochatzis EA. Downstaging for hepatocellular cancer: harm or benefit?. Transl Gastroenterol Hepatol 2017; 2 (Dec): 106
    CrossrefPubMedGoogle Scholar
  • 68 Lewandowski RJ, Kulik LM, Riaz A. , et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9 (08) 1920-1928
    CrossrefPubMedGoogle Scholar
  • 69 Lencioni R, Llovet JM, Han G. , et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016; 64 (05) 1090-1098
    CrossrefPubMedGoogle Scholar
  • 70 Gordon A, Lewandowski R, Hickey R. , et al. Prospective randomized phase 2 study of chemoembolization versus radioembolization in hepatocellular carcinoma: results from the PREMIERE trial. J Vasc Interv Radiol 2016; 27 (03) S61-S62
    PubMedGoogle Scholar
  • 71 Casadei Gardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, Sangro B. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. OncoTargets Ther 2018; 11: 7315-7321
    PubMedGoogle Scholar
  • 72 Klompenhouwer EG, Dresen RC, Verslype C. , et al. Safety and efficacy of transarterial radioembolisation in patients with intermediate or advanced stage hepatocellular carcinoma refractory to chemoembolisation. Cardiovasc Intervent Radiol 2017; 40 (12) 1882-1890
    CrossrefPubMedGoogle Scholar
  • 73 Marrero JA, Kulik LM, Sirlin CB. , et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68 (02) 723-750
    CrossrefPubMedGoogle Scholar
  • 74 Llovet JM, Ricci S, Mazzaferro V. , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390
    CrossrefPubMedGoogle Scholar
  • 75 Georgiades CS, Hong K, D'Angelo M, Geschwind JFH. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16 (12) 1653-1659
    CrossrefPubMedGoogle Scholar
  • 76 Silva JP, Berger NG, Tsai S. , et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford) 2017; 19 (08) 659-666
    CrossrefPubMedGoogle Scholar
  • 77 Abdalla EK, Stuart K. Overview of treatment approaches for hepatocellular carcinoma - UpToDate. Available at: https://www-uptodate-com.proxy.library.rcsi.ie/contents/overview-of-treatment-approaches-for-hepatocellular-carcinoma?search=hcc&topicRef=3599&source=see_link#H4 . Accessed November 10, 2019
    PubMedGoogle Scholar
  • 78 Li L, Zhao W, Wang M. , et al. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2018; 18 (01) 138 . Doi: 10.1186/s12876-018-0849-0
    CrossrefPubMedGoogle Scholar
  • 79 Abdel-Rahman OM, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2016; 2: CD011313
    PubMedGoogle Scholar
  • 80 Vilgrain V, Pereira H, Assenat E. , et al; SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18 (12) 1624-1636
    CrossrefPubMedGoogle Scholar
  • 81 Ricke J, Klümpen HJ, Amthauer H. , et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 2019; 71 (06) 1164-1174
    CrossrefPubMedGoogle Scholar
  • 82 Edeline J, Crouzet L, Campillo-Gimenez B. , et al. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging 2016; 43 (04) 635-643
    CrossrefPubMedGoogle Scholar
  • 83 Xing M, Kokabi N, Camacho JC, Kim HS. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. BMC Cancer 2018; 18 (01) 75
    CrossrefPubMedGoogle Scholar
  • 84 Gupta A, Dixon E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017; 6 (02) 101-104
    CrossrefPubMedGoogle Scholar
  • 85 Tan JCC, Coburn NG, Baxter NN, Kiss A, Law CHL. Surgical management of intrahepatic cholangiocarcinoma--a population-based study. Ann Surg Oncol 2008; 15 (02) 600-608
    CrossrefPubMedGoogle Scholar
  • 86 Valle J, Wasan H, Palmer DH. , et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
    CrossrefPubMedGoogle Scholar
  • 87 Yang L, Shan J, Shan L, Saxena A, Bester L, Morris DL. Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Oncol 2015; 6 (05) 570-588
    PubMedGoogle Scholar
  • 88 Zhen Y, Liu B, Chang Z, Ren H, Liu Z, Zheng J. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. OncoTargets Ther 2019; 12: 4489-4498
    CrossrefPubMedGoogle Scholar
  • 89 Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. ; ESMO Guidelines Committee. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl. 05) v28-v37
    CrossrefPubMedGoogle Scholar
  • 90 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69 (01) 7-34
    CrossrefPubMedGoogle Scholar
  • 91 Ghiringhelli F, Hennequin A, Drouillard A, Lepage C, Faivre J, Bouvier AM. Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study. Dig Liver Dis 2014; 46 (09) 854-858
    CrossrefPubMedGoogle Scholar
  • 92 Figueras J, Ramos E, López-Ben S. , et al. Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile?. Clin Transl Oncol 2007; 9 (06) 392-400
    CrossrefPubMedGoogle Scholar
  • 93 Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006; 244 (02) 254-259
    CrossrefPubMedGoogle Scholar
  • 94 Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23 (20) 4553-4560
    CrossrefPubMedGoogle Scholar
  • 95 Holen KD, Saltz LB. New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. Lancet Oncol 2001; 2 (05) 290-297
    CrossrefPubMedGoogle Scholar
  • 96 Fiorentini G, Aliberti C, Tilli M. , et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32 (04) 1387-1395
    PubMedGoogle Scholar
  • 97 Benson AB, Venook AP, Al-Hawary MM. , et al. NCCN guidelines insights: colon cancer, version 2.2018. J Natl Compr Canc Netw 2018; 16 (04) 359-369
    CrossrefPubMedGoogle Scholar
  • 98 Van Cutsem E, Cervantes A, Adam R. , et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27 (08) 1386-1422
    CrossrefPubMedGoogle Scholar
  • 99 Kemeny N, Kurilova I, Li J, Camacho JC, Sofocleous CT. Liver-directed and systemic therapies for colorectal cancer liver metastases. Cardiovasc Intervent Radiol 2019; 42 (09) 1240-1254
    CrossrefPubMedGoogle Scholar
  • 100 Martin II RCG, Scoggins CR, Schreeder M. , et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 2015; 121 (20) 3649-3658
    CrossrefPubMedGoogle Scholar
  • 101 Hendlisz A, Van den Eynde M, Peeters M. , et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28 (23) 3687-3694
    CrossrefPubMedGoogle Scholar
  • 102 Wasan HS, Gibbs P, Sharma NK. , et al; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 2017; 18 (09) 1159-1171
    CrossrefPubMedGoogle Scholar
  • 103 Zacharias AJ, Jayakrishnan TT, Rajeev R. , et al. Comparative effectiveness of hepatic artery based therapies for unresectable colorectal liver metastases: A meta-analysis. PLoS One 2015; 10 (10) e0139940
    CrossrefPubMedGoogle Scholar
  • 104 Levy J, Zuckerman J, Garfinkle R. , et al. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis. HPB (Oxford) 2018; 20 (10) 905-915
    CrossrefPubMedGoogle Scholar
  • 105 Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res 2018; 10: 5629-5638
    CrossrefPubMedGoogle Scholar
  • 106 Pavel M, O'Toole D, Costa F. , et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016; 103 (02) 172-185
    CrossrefPubMedGoogle Scholar
  • 107 Shah MH, Goldner WS, Halfdanarson TR. , et al. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw 2018; 16 (06) 693-702
    CrossrefPubMedGoogle Scholar
  • 108 de Baere T, Deschamps F, Tselikas L. , et al. GEP-NETS update: interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol 2015; 172 (04) R151-R166
    CrossrefPubMedGoogle Scholar
  • 109 Dermine S, Palmieri L-J, Lavolé J. , et al. Non-pharmacological therapeutic options for liver metastases in advanced neuroendocrine tumors. J Clin Med 2019; 8 (11) 1907
    CrossrefPubMedGoogle Scholar
  • 110 Maire F, Lombard-Bohas C, O'Toole D. , et al. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology 2012; 96 (04) 294-300
    CrossrefPubMedGoogle Scholar
  • 111 Gupta S, Johnson MM, Murthy R. , et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104 (08) 1590-1602
    CrossrefPubMedGoogle Scholar
  • 112 Guiu B, Deschamps F, Aho S. , et al. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 2012; 56 (03) 609-617
    CrossrefPubMedGoogle Scholar
  • 113 Walter T, Lepage C, Coriat R. , et al; FFCD 1104 investigators/investigators. Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study. Eur J Cancer 2019; 123: 92-100
    CrossrefPubMedGoogle Scholar
  • 114 Liao XF, Yi JL, Li XR, Deng W, Yang ZF, Tian G. Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol 2004; 10 (13) 1885-1889
    CrossrefPubMedGoogle Scholar
  • 115 Zener R, Yoon H, Ziv E. , et al. Outcomes after transarterial embolization of neuroendocrine tumor liver metastases using spherical particles of different sizes. Cardiovasc Intervent Radiol 2019; 42 (04) 569-576
    CrossrefPubMedGoogle Scholar
  • 116 Strosberg JR, Weber JM, Choi J. , et al. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol 2012; 23 (09) 2335-2341
    CrossrefPubMedGoogle Scholar
  • 117 Su Y-K, Mackey RV, Riaz A. , et al. Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J Vasc Interv Radiol 2017; 28 (11) 1520-1526
    CrossrefPubMedGoogle Scholar
  • 118 Tomozawa Y, Jahangiri Y, Pathak P. , et al. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol 2018; 29 (06) 858-865
    CrossrefPubMedGoogle Scholar
  • 119 de Mestier L, Zappa M, Hentic O, Vilgrain V, Ruszniewski P. Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord 2017; 18 (04) 459-471
    CrossrefPubMedGoogle Scholar
  • 120 Gaba RC, Lakhoo J. Yttrium-90 microsphere radioembolization for treatment of lung cancer hepatic metastases. Case Rep Oncol 2012; 5 (02) 479-486
    CrossrefPubMedGoogle Scholar
  • 121 Kis B, Shah J, Choi J. , et al. Transarterial yttrium-90 radioembolization treatment of patients with liver-dominant metastatic renal cell carcinoma. J Vasc Interv Radiol 2017; 28 (02) 254-259
    CrossrefPubMedGoogle Scholar
  • 122 Wang M, Zhang J, Ji S. , et al. Transarterial chemoembolisation for breast cancer with liver metastasis: a systematic review. Breast 2017; 36: 25-30
    CrossrefPubMedGoogle Scholar
  • 123 Rowcroft A, Loveday BPT, Thomson BNJ, Banting S, Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford) 2020; 22 (04) 497-505
    CrossrefPubMedGoogle Scholar
  • 124 Bale R, Putzer D, Schullian P. Local treatment of breast cancer liver metastasis. Cancers (Basel) 2019; 11 (09) E1341
    CrossrefPubMedGoogle Scholar
  • 125 Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44 (11) 4651-4659
    CrossrefPubMedGoogle Scholar
  • 126 Singh M, Durairaj P, Yeung J. Uveal melanoma: a review of the literature. Oncol Ther 2018; 6 (01) 87-104
    CrossrefPubMedGoogle Scholar
  • 127 Seedor RS, Eschelman DJ, Gonsalves CF. , et al. An outcome assessment of a single institution's longitudinal experience with uveal melanoma patients with liver metastasis. Cancers (Basel) 2020; 12 (01) E117
    CrossrefPubMedGoogle Scholar
  • 128 Gerbes A, Zoulim F, Tilg H. , et al. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut 2018; 67 (02) 380-388
    CrossrefPubMedGoogle Scholar
  • 129 Duffy AG, Ulahannan SV, Makorova-Rusher O. , et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017; 66 (03) 545-551
    CrossrefPubMedGoogle Scholar
  • 130 Dendy MS, Ludwig JM, Stein SM, Kim HS. Locoregional therapy, immunotherapy and the combination in hepatocellular carcinoma: future directions. Liver Cancer 2019; 8 (05) 326-340
    CrossrefPubMedGoogle Scholar
  • 131 Zhan C, Ruohoniemi D, Shanbhogue KP. , et al. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol 2020; 31 (01) 25-34
    CrossrefPubMedGoogle Scholar
  • 132 Yordanova A, Eppard E, Kürpig S. , et al. Theranostics in nuclear medicine practice. OncoTargets Ther 2017; 10: 4821-4828
    PubMedGoogle Scholar
  • 133 Strosberg J, El-Haddad G, Wolin E. , et al. Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 12 (36) 125-135
    PubMedGoogle Scholar
  • 134 Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 2010; 62 (11) 1052-1063
    CrossrefPubMedGoogle Scholar
  • 135 Lee ST, Kulkarni HR, Singh A, Baum RP. Theranostics of neuroendocrine tumors. Visc Med 2017; 33 (05) 358-366
    CrossrefPubMedGoogle Scholar
  • 136 Singh A, Zhang J, Kulkarni HBR. Intra-arterial PRRT of SSTR-expressing tumors in patients with hepatic only versus extrahepatic tumor: efficacy and safety evaluation. J Nucl Med 2019; 60 (Suppl. 01) 625
    PubMedGoogle Scholar
  • 137 Lee IJ, Ahn C-H, Cha E-J, Chung IJ, Chung JW, Kim YI. Improved drug targeting to liver tumors after intra-arterial delivery using superparamagnetic iron oxide and iodized oil: preclinical study in a rabbit model. Invest Radiol 2013; 48 (12) 826-833
    CrossrefPubMedGoogle Scholar
  • 138 Tian M, Lu W, Zhang R. , et al. Tumor uptake of hollow gold nanospheres after intravenous and intra-arterial injection: PET/CT study in a rabbit VX2 liver cancer model. Mol Imaging Biol 2013; 15 (05) 614-624
    CrossrefPubMedGoogle Scholar
  • 139 Murata S, Mine T, Sugihara F. , et al. Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20 (37) 13453-13465
    CrossrefPubMedGoogle Scholar
  • 140 Morshid A, Elsayes KM, Khalaf AM. , et al. A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization. Radiol Artif Intell 2019; 1 (05) e180021
    PubMedGoogle Scholar
  • 141 Letzen B, Wang CJ, Chapiro J. The Role of Artificial Intelligence in Interventional Oncology: A Primer. J Vasc Interv Radiol 2019; 30 (01) 38.e1-41.e1
    PubMedGoogle Scholar
  • 142 Reimer RP, Reimer P, Mahnken AH. Assessment of therapy response to transarterial radioembolization for liver metastases by means of post-treatment mri-based texture analysis. Cardiovasc Intervent Radiol 2018; 41 (10) 1545-1556
    CrossrefPubMedGoogle Scholar
  • 143 David K, Robertson I. Interventional Radiology A Survival Guide. 3rd ed. Amsterdam: Elsevier; 2011
    Google Scholar
  • 144 Vaidya S, Tozer KR, Chen J. An overview of embolic agents. Semin Intervent Radiol 2008; 25 (03) 204-215
    Article in Thieme ConnectPubMedGoogle Scholar
  • 145 Kritzinger J, Klass D, Ho S. , et al. Hepatic embolotherapy in interventional oncology: technology, techniques, and applications. Clin Radiol 2013; 68 (01) 1-15
    CrossrefPubMedGoogle Scholar
  • 146 Zechlinski JJ, Rilling WS. Transarterial therapies for the treatment of intrahepatic cholangiocarcinoma. Semin Intervent Radiol 2013; 30 (01) 21-27
    Article in Thieme ConnectPubMedGoogle Scholar
  • 147 Duran R, Chapiro J, Schernthaner RE, Geschwind J-FH. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol 2015; 88 (1052): 20140564
    CrossrefPubMedGoogle Scholar
  • 148 Rand T, Loewe C, Schoder M. , et al. Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. Cardiovasc Intervent Radiol 2005; 28 (03) 313-318
    CrossrefPubMedGoogle Scholar
  • 149 Maluccio MA, Covey AM, Porat LB. , et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2008; 19 (06) 862-869
    CrossrefPubMedGoogle Scholar
  • 150 Varela M, Real MI, Burrel M. , et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46 (03) 474-481
    CrossrefPubMedGoogle Scholar
  • 151 Lee EW, Khan S. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma. Clin Mol Hepatol 2017; 23 (04) 265-272
    CrossrefPubMedGoogle Scholar
  • 152 Liu DM, Thakor AS, Baerlocher M. , et al. A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof. Future Oncol 2015; 11 (09) 1421-1428
    CrossrefPubMedGoogle Scholar
  • 153 Bhagat N, Reyes DK, Lin M. , et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol 2013; 36 (02) 449-459
    CrossrefPubMedGoogle Scholar